CTLA4 and breast cancer: Here, we used the clinically relevant KEP-based mastectomy model for spontaneous multi-organ breast cancer metastasis39, which is unresponsive to anti-PD-1/anti-CTLA4 therapy, to demonstrate that systemic immunosuppression driven by Tregs prevents an effective anti-metastatic immune response upon neoadjuvant immunotherapy.